Gastrointestinal manifestations in myotonic muscular dystrophy - ARPI
Cell and animal models of DM1 have been crucial to providing insight into disease mechanisms and to revealing new therapeutic targets.
Protocole National de Diagnostic et de Soins (PNDS) Dystrophie ...Recent achievements carried out on lipid nanoparticles enabling gene therapy with the approval of treatment for rare disease as Onpattro® and ... Molecular Therapies for Myotonic Dystrophy Type 1 - CNR IrisSince a curative treatment for DM1 is not yet available, patient management also requires frequent screening for possible disease complications. Drug delivery nanosystems for skeletal muscle treatment in myotonic ...Patients reported limited benefits from the symptomatic therapies available. They hope for a treatment that will halt or slow disease ...
Autres Cours:
